Company profile for Alto Neuroscience

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

To bring every person suffering from a mental health condition the right treatment for them, right away. Alto Neuroscience is a clinical-stage biopharmaceutical company that integrates the biology of the patient into drug development to improve the lives of people with mental health conditions. Through our AI-enabled biomarker platform, we combine rich sources of information on patients’ brain activity and behavior to rapid...
To bring every person suffering from a mental health condition the right treatment for them, right away. Alto Neuroscience is a clinical-stage biopharmaceutical company that integrates the biology of the patient into drug development to improve the lives of people with mental health conditions. Through our AI-enabled biomarker platform, we combine rich sources of information on patients’ brain activity and behavior to rapidly develop highly-effective medicines for targeted populations. We aim to replace today's trial-and-error clinical approach by aligning the right Alto drug with the right patient

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
369 South San Antonio Road Los Altos, CA 94022
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20251112497891/en/Alto-Neuroscience-Reports-Third-Quarter-2025-Financial-Results-and-Recent-Business-Highlights

BUSINESSWIRE
12 Nov 2025

https://www.businesswire.com/news/home/20251028146760/en/Alto-Neuroscience-to-Participate-in-Upcoming-Investor-Conferences

BUSINESSWIRE
28 Oct 2025

https://www.businesswire.com/news/home/20251020503608/en/Alto-Neuroscience-Announces-%2450-Million-Private-Placement-Financing

BUSINESSWIRE
20 Oct 2025

https://www.businesswire.com/news/home/20251020895285/en/Alto-Neuroscience-Announces-Plans-to-Accelerate-Development-of-ALTO-207-in-Treatment-Resistant-Depression-Following-Successful-Outcome-from-Recent-FDA-Meeting

BUSINESSWIRE
20 Oct 2025

https://www.businesswire.com/news/home/20251003096029/en/Alto-Neuroscience-Receives-FDA-Fast-Track-Designation-for-ALTO-101-for-the-Treatment-of-Cognitive-Impairment-Associated-with-Schizophrenia

BUSINESSWIRE
03 Oct 2025

https://www.businesswire.com/news/home/20250909814928/en/Alto-Neuroscience-Announces-Robust-Replication-of-EEG-Biomarker-to-Objectively-Identify-Patients-with-Cognitive-Impairment-in-Schizophrenia

BUSINESSWIRE
09 Sep 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty